Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine and Oxaliplatin , can be used for G/GEJ cancer study.
References:
[1]. Shen L, et al. Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002)[J]. 2023. [2]. Park Soon Jae, et al. Pharmaceutical composition comprising human aluronidase PH20 variants for drug delivery system via subcutaneous injection. World Intellectual Property Organization, WO2023075506 A1. 2023-05-04.